Condition: Solid Cancer · Non-Small Cell Lung Cancer · Melanoma · Sponsor: Goethe University
The aim of this clinical study is to learn more about the effects of urolithin A (MitoPure®) on the immune system of cancer patients receiving immune checkpoint inhibitor-based therapies. Any effects will be compared with patients who take a placebo instead of urolithin A (MitoPure®).
This description comes directly from the study's public registry record.
Fabian Acker, MD · 06963015970 · acker@med.uni-frankfurt.de
Always discuss trial participation with your own doctor first.
| Universitätsklinikum Frankfurt, Medizinische Klinik II, Hämatologie/Onkologie | Frankfurt, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07161310